Association between spontaneous ovulation and serum anti-Müllerian hormone levels in a premature ovarian insufficiency patient after a multimodal treatment for breast cancer.
anti-Müllerian hormone
breast cancer survivor
fertility preservation
ovarian reserve
premature ovarian insufficiency
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
25
02
2019
accepted:
14
08
2019
pubmed:
29
8
2019
medline:
1
4
2020
entrez:
29
8
2019
Statut:
ppublish
Résumé
The high toxicity of chemotherapy can damage a patient's gonadal function, leading to premature ovarian insufficiency (POI). Here, we report the case of a patient suffering from POI after chemotherapy for breast cancer, who 3 years later ovulated spontaneously and became pregnant. The patient, a 31-year-old infertile women, nulligravida, was diagnosed with breast cancer. The Anti-Müllerian Hormone (AMH) level in her serum was 1.85 ng/mL before multimodal treatment for cancer. She later visited our hospital for amenorrhea and 2 years after cancer treatment, she was diagnosed with POI. Her AMH level at that point was less than 0.1 ng/mL. One year after the diagnosis of POI, the patient's AMH level increased slightly to 0.14 ng/mL and she ovulated spontaneously. The patient later became pregnant using Assisted Reproductive Technology on the fourth attempt.During the course of treatment for infertility at our hospital, the AMH levels in her serum changed along with the recovery of ovarian function. These findings suggest the possibility that ovulation and pregnancy could be predicted by the chronological changes of the AMH levels in the patient's serum.
Substances chimiques
Anti-Mullerian Hormone
80497-65-0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
2297-2301Informations de copyright
© 2019 Japan Society of Obstetrics and Gynecology.
Références
Morarji K, McArdle O, Hui K et al. Ovarian function after chemotherapy in young breast cancer survivors. Curr Oncol 2017; 24: 494-502.
Brougham MF, Crofton PM, Johnson EJ et al. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: A prospective study. J Clin Endocrinol Metab 2012; 97: 2059-2067.
Maruyama T, Miyazaki K, Uchida H, Uchida S, Masuda H, Yoshimura Y. Achievement of pregnancies in women with primary ovarian insufficiency using close monitoring of follicle development: Case reports. Endocr J 2013; 60: 791-797.
Miyoshi Y, Yasuda K, Tachibana M et al. Longitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment. Clin Pediatr Endocrinol 2016; 25: 119-126.
Lee SJ, Schover LR, Partridge AH et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-2931.
Koike M, Kanda A, Kido K et al. Effects of cyclophosphamide administration on the in vitro fertilization of mice. Reprod Med Biol 2018; 17: 262-267.
Erickson G. Follicle growth and development. Glob Libr Women Med 2008; doi: 10.3843/GLOWM.10289
Komatsu K, Masubuchi S. Observation of the dynamics of follicular development in the ovary. Reprod Med Biol 2017; 16: 21-27.
Anderson RA, Cameron DA. Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011; 96: 1336-1343.
Morel N, Bachelot A, Chakhtoura Z et al. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab 2013; 98: 3785-3792.
Köninger A, Kauth A, Schmidt B et al. Anti-Mullerian-hormone levels during pregnancy and postpartum. Reprod Biol Endocrinol 2013; 11: 60.
La Marca A, Giulini S, Orvieto R et al. Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 2005; 20: 1569-1572.
Takai Y. Recent advances in oncofertility care worldwide and in Japan. Reprod Med Biol 2018; 17: 356-368.
Ukita Y, Wakimoto Y, Sugiyama Y et al. Fertility preservation and pregnancy outcomes in adolescent and young adult male patients with cancer. Reprod Med Biol 2018; 17: 449-453.
Loren AW, Mangu PB, Beck LN et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500-2510.
Wakimoto Y, Akatani-Hasegawa A, Wakimoto G et al. Fertility preservation for adolescent and young adult women in Hyogo College of Medicine College hospital. Acta Medica Hyogoensia 2017; 42: 101-107.
Hadlow N, Brown SJ, Habib A et al. Quantifying the intraindividual variation of anti Müllerian hormone in the ovarian cycle. Fertil Steril 2016; 106: 1230-1237.
European Society for Human Reproduction and Embryology. (ESHRE) guideline group on POI, Webber L, Davies M et al. ESHRE guideline: Management of women with premature ovarian insufficiency. Hum Reprod 2016; 31: 926-937.